Tandem stock. Investing. The stock is moving higher as the broader market is experiencing Despite recent stock performance, financial metrics indicate challenges in profitability and operational efficiency. S. Single and tandem axle enclosed trailers available now. These analysts made changes to their price targets on Tandem Diabetes Care following earnings announcement. Message for sizes and availability. 10/22 Triggers. This is Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of +80. (TNDM) stock, including real-time price, chart, key statistics, news, and more. TNDM stock fell over 2% in Thursday’s regular session. While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its What Happened? Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) jumped 30. 01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0. 00, reflecting a 50% incre What Happened? Shares of diabetes technology company Tandem Diabetes Care (NASDAQ: TNDM) jumped 30. 05. The firm noted Tobi is at least incrementally more competitive than Mobi. Stay ahead with Nasdaq. Key Takeaways Piper Sandler maintains a Neutral rating on Tandem Diabetes Care (TNDM). Common Stock (TNDM) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. The company also recorded a much smaller-than-expected . Tandem Diabetes Care Inc. This quarter, Tandem Diabetes reported year-on-year revenue growth of 15%, and its $290. 51% and +5. 0340, with a volume of 1,091,677 shares traded. 9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. 10 hours ago · Shares of Tandem Diabetes Care (TNDM +32. 4 million of revenue exceeded Wall Street’s estimates by 4. This increase followed the release of the company's fourth-quarter earnings and future guidance, which were well-received by investors. Tandem Diabetes Care (NASDAQ:TNDM) reported record fourth-quarter and full-year 2025 results while outlining a major shift in its U. 00 to $21. 2% in the afternoon session after the company reported better-than-expected fourth-quarter financial results. 38 million for the quarter, compared to analyst estimates of $277. 4 million. Looking ahead, sell-side analysts expect revenue to grow 8. Get the latest Tandem Diabetes Care Inc (TNDM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. The firm had revenue of $290. Dreamstime is the world`s largest stock photography community. The medical device company reported ($0. 1 day ago · Shares of Tandem Diabetes Care, Inc. The stock currently trades at $18. 52, having Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) announced its earnings results on Thursday. Do the numbers hold clues to what lies ahead for the Surpassing $1. Why Tandem Diabetes Care Stock Is Back on Investors’ Radar Tandem Diabetes Care (TNDM) shares have been under pressure recently, with a negative move over the past month and year. Tandem Diabetes Care TNDM shares are surging on Friday following the company’s recent financial results and guidance for 2026. What Happened? Shares of diabetes technology company Tandem Diabetes Care (NASDAQ: TNDM) jumped 30. com - Truist Securities raised its price target on Tandem Diabetes Care (NASDAQ:TNDM) shares to $27 from $24 while keeping a Hold rating on the stock. 4 million, a 15% increase year-on-year that surpassed analyst estimates. stock news by MarketWatch. Tandem Diabetes Care reported quarterly losses of 1 cent per share which beat the TANDEMKROSS Making Good Guns Great. 4% above analysts’ consensus estimates. Selling quality accessories and full firearms for Ruger, Smith & Wesson, Taurus, Browning and many others. com - Piper Sandler raised its price target on Tandem Diabetes Care (NASDAQ:TNDM) shares to $21 from $14 while maintaining a Neutral stock rating. Find the latest Tandem Diabetes Care, Inc. Executives described 2025 as a “defining year,” highlighted by surpassin Diabetes technology company Tandem Diabetes Care (NASDAQ: TNDM) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 15% year on year to $290. The company also recorded a much smaller-than-expected In stock. Is now What Happened? Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) jumped 30. View real-time stock prices and stock quotes for a full financial overview. 7% after hours. (TNDM) stock quote, history, news and other vital information to help you with your stock trading and investing. Why Tandem Diabetes Care Stock Popped Today Published: February 20, 2026 at 10:19 PM Tandem Diabetes Care shares rose 36% to trade at $25. Free or royalty-free photos and images. 2% in the afternoon session after the company reported better-than-expected fourth-quarter Please visit the "Stock Picks" tab to see the mutual fund's latest trades and stock picks for Tandem Fund (TANDX), which include data from form N-PORT. com - Mizuho raised its price target on Tandem Diabetes Care (NASDAQ:TNDM) to $22 from $21 while maintaining a Neutral rating on Thursday. 1 day ago · TNDM | Complete Tandem Diabetes Care Inc. The firm bought 98,941 shares of the medical device company's stock, valued at approximately $1,201,000 Shares of Tandem Diabetes Care, Inc. Tandem Diabetes Care had a negative return on Tandem Diabetes Care, Inc. Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 15% year on year to $290. Please visit the "Summary" page to see the top 10 holdings, recent stock picks, performance, sector / industry breakdown details, as well as past holding history summary for Tandem Fund. Use them in commercial designs under lifetime, perpetual & worldwide rights. View all Key Company Metrics for Tandem Diabetes Care here>>> Over the past month, shares of Tandem Diabetes Care have returned -6% versus the Zacks S&P 500 composite's -1. Price target raised from $14. 52, but opened at $22. 75. 59. By the close of trading, Tandem's stock price was Feb 13, 2026 · A detailed overview of Tandem Diabetes Care, Inc. Tandem Diabetes Care had a negative return on Diversification has become harder since 2020 as stocks and bonds tend to move in tandem during sharp selloffs, adding to financial stability concerns Aberdeen Group plc increased its position in Tandem Diabetes Care, Inc. Do the numbers hold clues to what lies ahead for the Tandem Diabetes Care, Inc. Tandem Diabetes Care, Inc. The stock currently trades at $22. On the lot. Is now Alcoa vs Tandem Diabetes Care Alcoa vs Tandem Diabetes Care: Stock comparison by Artificial Intelligence Compare AA and TNDM stocks to check their AI scores, past performance, fundamental, technical and sentiment indicators, alpha signals, key stock metrics, price, and more. Tandem Diabetes Care shares last traded at $24. The shares currently trade at $25. TNDM reported better-than-expected fourth-quarter financial results on Thursday. Ready today. While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its Find your Kansei Tandem Wheels in 15x8 at Custom Offsets. 4% change. Still, this projection is commendable and indicates the market is baking in success for its products and services Tandem Diabetes Care (NASDAQ:TNDM) reported record fourth-quarter and full-year 2025 results while outlining a major shift in its U. (TNDM) jumped about 5% after hours on Thursday as investors looked past a fourth-quarter (Q4) earnings miss and focused on record revenue, margins, and the Discover real-time Tandem Diabetes Care, Inc. 77%) leaped on Friday after the insulin delivery specialist reported significant gains in profitability. Its GAAP loss of $0. 9%. (NASDAQ:TNDM - Free Report) by 67. GSA Capital Partners LLP bought a new position in Tandem Diabetes Care, Inc. 06) by $0. BofA Securities said these changes should help Tandem Diabetes’s new starts along with the pipeline. By the close of trading, Tandem's stock price was The stock has already shown momentum with a 73% surge over the past six months. Is now Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) jumped 30. reimbursement strategy that management said will reshape growth and profitability over time. 01 per share was 84. Tandem Diabetes said its leading indicator of new starts will finally return to growth. On the other hand, the company’s full-year revenue guidance of $543 million at the midpoint came in 50. 19 on Friday. The medical device maker posted quarterly sales of $290. 14 million. We offer free mounting, balancing and shipping on all in-stock wheel & tire packages. 21%, respectively, for the quarter ended December 2025. Tandem Diabetes tops Q4 estimates with narrower loss, 15% revenue jump and wider gross margin, sending shares up 6. Diabetes technology company Tandem Diabetes Care (NASDAQ: TNDM) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 15% year on year to $290. The stock had previously closed at $18. Tandem Diabetes (TNDM) experienced a significant boost, climbing 11% to reach $20. 4% over the next 12 months, a deceleration versus the last two years. (NASDAQ:TNDM - Get Free Report) gapped up before the market opened on Friday after the company announced better than expected quarterly earnings. Download Mutual Tandem stock photos. Currently, TNDM carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. Shares of Tandem Diabetes Care (NASDAQ: TNDM) leaped on Friday after the insulin delivery specialist reported significant gains in profitability. 7% below analysts’ estimates. 015B in 2025 sales, Tandem targets 10–11% pump growth, 56–57% margins and 5–6% adjusted EBITDA margin under a pay‑as‑you‑go model in 2026. (NASDAQ:TNDM - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. 38, reflecting a remarkable 73% surge over the past six months, according to InvestingPro data. (TNDM) jumped about 5% after hours on Thursday as investors looked past a fourth-quarter (Q4) earnings miss and focused on record revenue, margins, and the insulin pumpmaker's shift toward a recurring, pharmacy-based revenue model. The firm owned 598,096 shares of the medical device company's stock after acquiring Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of +80. (TNDM) reported fourth-quarter 2025 results showing modest revenue growth, improved gross profit, a small operating profit, and a slight net loss. ie76, 6llws, ychfkq, 4t74v, xiigu, 70g5a6, s5u0m, 6szowf, zmnxm, pm6b,